Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Southeast Asian J Trop Med Public Health ; 2001 Mar; 32(1): 64-9
Artigo em Inglês | IMSEAR | ID: sea-34790

RESUMO

Using standard in vitro drug susceptibility methods, we assessed the antimalarial activity of 3 orally administered iron chelators (hydroxypyridinones) alone and in combination with conventional antimalarials drugs (quinine, mefloquine, artesunate, tetracycline, atovaquone) against a chloroquine-resistant Plasmodium falciparum isolate. When tested alone, all iron chelators and antimalarial compounds inhibited the growth of the parasites. IC50 values for iron chelators were 60-70 microM, whereas the IC50 values for antimalarial drugs were in nM ranges, with artesunate being the most potent. The derived isobolograms for the interaction of hydroxypyridinones and antimalarial drugs showed addition or mild antagonism, similar to desferroxamine (Sum of Fractional Inhibitory Concentration, sigma FIC < 0.5 or > 4.0). Despite the absence of synergy with conventional drugs, intrinsic antimalarial activity of hydroxypyridinones supports the continued assessment of these iron chelators as treatment adjuncts.


Assuntos
Animais , Antimaláricos/administração & dosagem , Quelantes de Ferro/administração & dosagem , Plasmodium falciparum/efeitos dos fármacos , Piridonas/administração & dosagem
2.
Southeast Asian J Trop Med Public Health ; 1996 Jun; 27(2): 216-20
Artigo em Inglês | IMSEAR | ID: sea-31741

RESUMO

Clinical studies have shown atovaquone (ATQ), a new blood schizontocidal drug, in combination with proguanil (PROG) to be very effective in the treatment of acute multidrug-resistant falciparum malaria. The multiple dose pharmacokinetics of PROG were determined in Thai patients with acute falciparum malaria given PROG alone (200 mg PROG twice a day for 3 days, n = 4) and concurrently PROG and ATQ (200 mg PROG and 500 mg ATQ twice a day for 3 days, n = 12). There were no statistical differences (p > 0.05) in the area under the plasma drug concentration-time curve (AUC), apparent oral clearance (CL/F) and elimination half-life (t1/2) of PROG between patients given PROG alone and PROG/ ATQ. The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6). The CL/F and t1/2 of PROG in the Thai patients treated with the 2 treatment regimens were also comparable to values reported in healthy Thai volunteers given a standard prophylactic dose (200 mg PROG). The results of this preliminary study suggest that ATQ is unlikely to affect the pharmacokinetics of PROG to a clinically important extent at an ATQ dosage of 500 mg twice a day for 3 days in malaria infected patients.


Assuntos
Doença Aguda , Adolescente , Adulto , Antimaláricos/farmacocinética , Atovaquona , Proguanil/farmacocinética , Relação Dose-Resposta a Droga , Resistência a Múltiplos Medicamentos , Sinergismo Farmacológico , Quimioterapia Combinada , Humanos , Absorção Intestinal , Malária Falciparum/tratamento farmacológico , Masculino , Taxa de Depuração Metabólica , Naftoquinonas/farmacocinética
3.
Southeast Asian J Trop Med Public Health ; 1993 Jun; 24(2): 230-4
Artigo em Inglês | IMSEAR | ID: sea-34384

RESUMO

The clinical results of this study indicate that a half-dose regimen of artesunate followed by mefloquine produces an acceptable cure rate when compared to other commonly available drugs for treating acute uncomplicated falciparum malaria in Thailand. The 90% cure rate was comparable to the results with either a full dose of artesunate (600 mg over 5 days) or mefloquine (25 mg/kg in divided doses six hours apart) as well as the combination of quinine-tetracycline administered for seven days. This abbreviated regimen, however was less effective than the full dose regimen of both drugs previously reported.


Assuntos
Doença Aguda , Adolescente , Adulto , Antimaláricos/administração & dosagem , Artemisininas , Esquema de Medicação , Resistência a Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Malária Falciparum/tratamento farmacológico , Masculino , Mefloquina/administração & dosagem , Pessoa de Meia-Idade , Sesquiterpenos/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA